AstraZeneca won’t submit lung drug for COPD after 2nd study miss
AstraZeneca no longer plans to seek approval of its new respiratory biologic Fasenra in chronic obstructive pulmonary disease (COPD) after the…
Owlstone Medical’s Breath Biopsy Platform integrated into GSK’s Phase II Respiratory Disease Clinical Trial
Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, today announced that GSK, a world leader in respiratory,…
GSK study shows COPD ‘superiority’ for Anoro Ellipta versus Stiolto Respimat
GlaxoSmithKline’s (GSK) study showed that Anoro Ellipta is more effective than Stiolto Respimat in improving lung function in patients with…